190 related articles for article (PubMed ID: 24202330)
1. The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy.
Green LK; Storey MA; Williams EM; Patterson AV; Smaill JB; Copp JN; Ackerley DF
Cancers (Basel); 2013 Aug; 5(3):985-97. PubMed ID: 24202330
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.
Green LK; Syddall SP; Carlin KM; Bell GD; Guise CP; Mowday AM; Hay MP; Smaill JB; Patterson AV; Ackerley DF
Mol Cancer; 2013 Jun; 12():58. PubMed ID: 23758947
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
[TBL] [Abstract][Full Text] [Related]
4. Engineering the
Sharrock AV; McManaway SP; Rich MH; Mumm JS; Hermans IF; Tercel M; Pruijn FB; Ackerley DF
Front Pharmacol; 2021; 12():701456. PubMed ID: 34163368
[TBL] [Abstract][Full Text] [Related]
5. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
[TBL] [Abstract][Full Text] [Related]
6. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
Vass SO; Jarrom D; Wilson WR; Hyde EI; Searle PF
Br J Cancer; 2009 Jun; 100(12):1903-11. PubMed ID: 19455141
[TBL] [Abstract][Full Text] [Related]
7. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
[TBL] [Abstract][Full Text] [Related]
8. Repurposing
Ruiz de Garibay G; García de Jalón E; Stigen E; Lund KB; Popa M; Davidson B; Safont MM; Rygh CB; Espedal H; Barrett TM; Haug BE; McCormack E
Theranostics; 2021; 11(12):6044-6057. PubMed ID: 33897898
[TBL] [Abstract][Full Text] [Related]
9. Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.
Copp JN; Mowday AM; Williams EM; Guise CP; Ashoorzadeh A; Sharrock AV; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
Cell Chem Biol; 2017 Mar; 24(3):391-403. PubMed ID: 28262557
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of NfsA-like nitroreductases from Neisseria meningitidis and Bartonella henselae for enzyme-prodrug therapy, targeted cellular ablation, and dinitrotoluene bioremediation.
Rich MH; Sharrock AV; Hall KR; Ackerley DF; MacKichan JK
Biotechnol Lett; 2018 Feb; 40(2):359-367. PubMed ID: 29147875
[TBL] [Abstract][Full Text] [Related]
11. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
12. Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.
Williams EM; Little RF; Mowday AM; Rich MH; Chan-Hyams JV; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem J; 2015 Oct; 471(2):131-53. PubMed ID: 26431849
[TBL] [Abstract][Full Text] [Related]
13. Engineering
Williams EM; Rich MH; Mowday AM; Ashoorzadeh A; Copp JN; Guise CP; Anderson RF; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
Biochemistry; 2019 Sep; 58(35):3700-3710. PubMed ID: 31403283
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
15. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
16. Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.
Ashoorzadeh A; Mowday AM; Guise CP; Silva S; Bull MR; Abbattista MR; Copp JN; Williams EM; Ackerley DF; Patterson AV; Smaill JB
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215297
[TBL] [Abstract][Full Text] [Related]
17. Nitroreductase-based GDEPT.
Denny WA
Curr Pharm Des; 2002; 8(15):1349-61. PubMed ID: 12052212
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel nitroreductases from Bacillus cereus and their interaction with the CB1954 prodrug.
Gwenin VV; Poornima P; Halliwell J; Ball P; Robinson G; Gwenin CD
Biochem Pharmacol; 2015 Dec; 98(3):392-402. PubMed ID: 26415543
[TBL] [Abstract][Full Text] [Related]
19.
Mowday AM; Copp JN; Syddall SP; Dubois LJ; Wang J; Lieuwes NG; Biemans R; Ashoorzadeh A; Abbattista MR; Williams EM; Guise CP; Lambin P; Ackerley DF; Smaill JB; Theys J; Patterson AV
Theranostics; 2020; 10(23):10548-10562. PubMed ID: 32929365
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]